Grantham, Mayo, Van Otterloo & Co (GMO)
VIVO

Grantham, Mayo, Van Otterloo & Co (GMO)’s Meridian Bioscience Inc VIVO Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-127,001
Closed -$4.22M – 788
2022
Q4 		$4.22M Buy
127,001
+116,701
+1,133% +$3.76M 0.02% 360
2022
Q3 		$325K Sell
10,300
-11,300
-52% -$366K ﹤0.01% 620
2022
Q2 		$657K Buy
+21,600
New +$584K ﹤0.01% 578
2021
Q4 		– Sell
-42,117
Closed -$810K – 758
2021
Q3 		$810K Sell
42,117
-30,700
-42% -$612K ﹤0.01% 553
2021
Q2 		$1.61M Sell
72,817
-29,400
-29% -$624K 0.01% 488
2021
Q1 		$2.68M Sell
102,217
-158,883
-61% -$3.78M 0.01% 431
2020
Q4 		$4.88M Sell
261,100
-154,600
-37% -$2.89M 0.03% 294
2020
Q3 		$7.06M Buy
415,700
+159,200
+62% +$3.09M 0.05% 193
2020
Q2 		$5.97M Buy
256,500
+211,500
+470% +$3.07M 0.04% 226
2020
Q1 		$378K Buy
+45,000
New +$379K ﹤0.01% 638

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s VIVO Position: Q1 2023 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 127,001 shares — an estimated $4.22M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in VIVO in Q1 2020 and held it in 10 quarters. The position peaked at $7.06M in Q3 2020. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 127,001 Meridian Bioscience Inc shares in Q1 2023, an estimated $4.22M.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Meridian Bioscience Inc in Q1 2020 and held it in 10 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Meridian Bioscience Inc position peaked at $7.06M in Q3 2020.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2023, filed 12 May 2023.